By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Hemispherx Biopharma Inc. 

One Penn Center
1617 JFK Boulevard
Philadelphia  Pennsylvania  19103  U.S.A.
Phone: 215-988-0080 Fax: 215-988-1739


SEARCH JOBS








Company News
Hemispherx Biopharma (HEB): Institute Of Medicine, The Health Arm Of The US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) As A "Systemic Exertion Intolerance Disease" (SEID) 2/23/2015 7:31:14 AM
Hemispherx Biopharma (HEB) And USAMRIID To Present New Discoveries Concerning The Efficacy Of Ampligen Against The Ebola Virus At Upcoming International Symposium On Filoviruses 2/12/2015 7:35:56 AM
Hemispherx Biopharma (HEB) Posts USAMRIID Ebola Study Concluding Ampligen Produced 100% Survival Rate In Rodents With 100% Mortality In Placebo 2/9/2015 7:37:25 AM
Hemispherx Biopharma (HEB): US Army Scientists (USAMRIID) Find Ampligen® Produces 100% Survival Rate In Ebola Virus Rodent Study 2/2/2015 10:33:28 AM
Hemispherx Biopharma (HEB): US Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate In Ebola Virus Rodent Study 2/2/2015 7:56:13 AM
Hemispherx Biopharma (HEB) Release: USAMRIID Reports Genetic Changes In Ebola Virus May Impede Potential Treatments 1/26/2015 7:49:23 AM
Hemispherx Biopharma (HEB) Awarded $770,852 by Federal Judge 1/15/2015 7:09:42 AM
Hemispherx Biopharma (HEB) Release: Low Natural Killer (NK) Activity Observed Across The Chronic Fatigue Syndrome (CFS) Disease Spectrum 1/12/2015 7:07:11 AM
Arrowhead Issues Diligence And Valuation Report On Hemispherx Biopharma (HEB) 1/9/2015 7:45:35 AM
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014 8:07:45 AM
12345678910...
//-->